Last reviewed · How we verify
BNP7787
BNP7787 is a cytoprotective agent that binds to and inactivates cisplatin, reducing its nephrotoxicity and neurotoxicity while preserving anti-tumor efficacy.
BNP7787 is a cytoprotective agent that binds to and inactivates cisplatin, reducing its nephrotoxicity and neurotoxicity while preserving anti-tumor efficacy. Used for Reduction of cisplatin-induced nephrotoxicity and neurotoxicity in patients receiving cisplatin-based chemotherapy.
At a glance
| Generic name | BNP7787 |
|---|---|
| Also known as | BNP7787 also known as Tavocept |
| Sponsor | Alliance for Clinical Trials in Oncology |
| Drug class | Cytoprotective agent / Cisplatin protectant |
| Target | Cisplatin (indirect; forms inactivating complex) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
BNP7787 (also known as mesna derivative) acts as a selective cytoprotective agent by forming a complex with cisplatin that prevents the drug from damaging normal tissues, particularly the kidneys and peripheral nerves. The complex allows cisplatin to retain its anti-cancer activity against tumor cells while reducing dose-limiting toxicities. This mechanism enables higher cisplatin doses or improved tolerability in chemotherapy regimens.
Approved indications
- Reduction of cisplatin-induced nephrotoxicity and neurotoxicity in patients receiving cisplatin-based chemotherapy
Common side effects
- Nausea
- Vomiting
- Fatigue
- Injection site reactions
Key clinical trials
- TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies (PHASE2)
- A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma (PHASE2)
- Phase 3 Study of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin (PHASE3)
- Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel (PHASE3)
- Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer (PHASE2)
- Dimesna in Treating Patients With Solid Tumors Who Are Undergoing Treatment With Cisplatin and Paclitaxel
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BNP7787 CI brief — competitive landscape report
- BNP7787 updates RSS · CI watch RSS
- Alliance for Clinical Trials in Oncology portfolio CI